DOCSLIB.ORG

Alphabetical Listing of ATC Drugs & Codes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alphabetical Listing of ATC Drugs & Codes Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04 0.1 g O Acepromazine N05AA04 50 mg P Acetarsol A07AX02 Acetarsol G01AB01 0.5 g V Acetarsol P01CD02 Acetazolamide S01EC01 0.75 g O,P Acetic acid G01AD02 Acetic acid S02AA10 Acetohexamide A10BB31 0.5 g O Acetohydroxamic acid G04BX03 0.75 g O Acetophenazine N05AB07 50 mg O Acetorphan A07XA04 Acetoxolone A02BX09 Acetphenolisatin A06AB01 10 mg O Acetrizoic acid V08AA07 Acetylcarnitine N06BX12 1/63 Acetylcholine S01EB09 Acetylcysteine R05CB01 0.5 g O Acetylcysteine R05CB01 1.6 g Inhal.solution Acetylcysteine S01XA08 Acetylcysteine V03AB23 Acetyldigitoxin C01AA01 0.2 mg O Acetyldigoxin C01AA02 0.5 mg O Acetylglycinamide chloral hydrate N05CC03 1.7 g O Acetylleucine N07CA04 Acetylsalicylic acid A01AD05 Acetylsalicylic acid B01AC06 1 tablet# Acetylsalicylic acid N02BA01 3 g O,R Acetylsalicylic acid N02BA01 1 g P Acetylsalicylic acid and corticosteroids M01BA03 Acetylsalicylic acid, comb. excl. psycholeptics N02BA51 Acetylsalicylic acid, comb. with psycholeptics N02BA71 Aciclovir D06BB03 Aciclovir J05AB01 4 g O,P Aciclovir S01AD03 Acipimox C10AD06 0.5 g O Acitretin D05BB02 35 mg O Aclarubicin L01DB04 Acriflavinium chloride R02AA13 Acrivastine R06AX18 24 mg O Adapalene D10AD03 Ademetionine A16AA02 Adenosine C01EB10 15 mg P Adinazolam N05BA07 Adipiodone V08AC04 Adrafinil N06BX17 Adrenalone A01AD06 Adrenalone B02BC05 Adrenergic & dopaminergic agents - combinations C01CA30 Ajmaline C01BA05 0.3 g O Alanyl glutamine B05XB02 Alaproclate N06AB07 Albendazole P02CA03 0.4 g O Albumin B05AA01 Albumin tannate A07XA01 3 g O Albumin tannate, combinations A07XA51 Alclofenac M01AB06 1.25 g O,R Alclometasone D07AB10 Alclometasone S01BA10 Alcuronium M03AA01 Aldesleukin L03AC01 Aldesulfone sodium J04BA03 0.33 g O Aldosterone H02AA01 Alendronic acid M05BA04 10 mg O Alfa1 antitrypsin B02AB02 Alfacalcidol A11CC03 1 mcg O,P Alfaxalone N01AX05 Alfentanil N01AH02 Alfuzosin G04CA01 7.5 mg O Algeldrate A02AB02 5 g O Alginic acid A02EA01 Alglucerase A16AB01 Alimemazine R06AD01 30 mg O,P Alizapride A03FA05 0.15 g O,P Allobarbital N05CA21 Allopurinol M04AA01 0.4 g O,P Allopurinol, combinations M04AA51 Allylestrenol G03DC01 10 mg O 2/63 Almagate A02AD03 Almasilate A02AD05 Alminoprofen M01AE16 Almitrine R07AB07 0.1 g O Aloglutamol A02AB06 Aloxiprin B01AC15 Aloxiprin N02BA02 3 g O Alprazolam N05BA12 1 mg O Alprenolol C07AA01 0.4 g O,P Alprostadil C01EA01 Alprostadil G04BE01 20 mcg P Alsactide V04CH04 Alteplase B01AD02 0.1 g P Alteplase S01XA13 Althea root R05CA05 1.6 g O Altizide and potassium-sparing agents C03EA04 Altretamine L01XX03 Alum S01XA07 Aluminium acetoacetate A02AB05 Aluminium acetotartrate C05AX01 Aluminium acetotartrate S02AA04 Aluminium chloride D10AX01 Aluminium chlorohydrate D09AA08 Aluminium chlorohydrate M05BX02 Aluminium clofibrate C10AB03 Aluminium compounds, combinations A02AB10 Aluminium glycinate A02AB07 Aluminium hydroxide A02AB01 Aluminium nicotinate C10AD04 Aluminium oxide D10AX04 Aluminium phosphate A02AB03 Alverine A03AX08 Alverine, combinations A03AX58 Amantadine N04BB01 0.2 g O Ambazone R02AA01 40 mg O Ambenonium N07AA30 60 mg O Ambroxol R05CB06 Ambutonium and psycholeptics A03CA07 Amcinonide D07AC11 Amfebutamone N06AX12 Amfepramone A08AA03 75 mg O Amfetamine N06BA01 15 mg O,P Amide anaesthetics, local, combinations N01BB20 Amifostine V03AF05 1.7 g P Amikacin D06AX12 Amikacin J01GB06 1 g P Amikacin S01AA21 Amiloride C03DB01 10 mg O Amineptine N06AA19 Amino acids B05BA01 Amino(diphenylhydantoin) valeric acid N03AB03 0.3 g O Aminoacridine D08AA02 Aminobenzoic acid D02BA01 Aminobutyric acid N03AG03 1 g O,P Aminocaproic acid B02AA01 16 g O,P Aminogluthetimide L02BG01 1 g O Aminohippuric acid V04CH30 Aminomethylbenzoic acid B02AA03 0.25 g O Aminophenazone N02BB03 0.5 g R Aminophenazone, combinations excl. psycholeptics N02BB53 Aminophenazone, combinations with psycholeptics N02BB73 Aminophylline R03DA05 0.6 g O,P,R 3/63 Aminophylline and adrenergics R03DB05 Aminophylline, combinations R03DA55 Aminosalicylic acid J04AA01 12 g O Amiodarone C01BD01 0.2 g O,P Amisulpride N05AL05 Amitriptyline N06AA09 75 mg O,P Amitriptyline and psycholeptics N06CA01 Amlexanox R03DX01 Amlodipine C08CA01 5 mg O Ammonium chloride B05XA04 Ammonium chloride G04BA01 8.5 g O Amobarbital N05CA02 0.1 g O,P Amodiaquine P01BA06 Amorolfine D01AE16 Amoxapine N06AA17 0.15 g O Amoxicillin J01CA04 1 g O,P Amoxicillin and enzyme inhibitor J01CR02 1 g O Amphotericin A01AB04 40 mg O Amphotericin A07AA07 0.4 g O Amphotericin G01AA03 0.2 g V Amphotericin J02AA01 35 mg P Ampicillin J01CA01 2 g O,P,R Ampicillin S01AA19 Ampicillin and enzyme inhibitor J01CR01 2 g P Ampicillin, combinations J01CA51 Amrinone C01CE01 0.5 g P Amsacrine L01XX01 Amyl nitrite V03AB22 Anagrelide B01AC14 Anastrozole L02BG03 1 mg O Ancestim L03AA12 Androstanolone A14AA01 Anesthetic ether (diethyl ether) N01AA01 Anethole trithione A16AX02 Angiotensinamide C01CX06 5 mg P Anileridine N01AH05 Animals V01AA11 Aniracetam N06BX11 Anistreplase B01AD03 30 U P Antazoline R01AC04 Antazoline R06AX05 0.3 g O,P Anthrax antigen J07AC01 Anti-D (rh) immunoglobulin J06BB01 Antibiotics in combination with other drugs S01AA20 Antifungals, dermatological, combinations D01AA20 Antiinfectives, combinations S02AA30 Antiinfectives, combinations S03AA30 Antilymphocyte immunoglobulin (horse) L04AA03 Antimony pentasulfide R05CA07 0.2 g O Antithrombin III B01AB02 2.1 TU P Antithymocyte immunoglobulin (rabbit) L04AA04 Apomorphine N04BC07 Apraclonidine S01EA03 Aprindine C01BB04 0.1 g O,P Aprobarbital N05CA05 0.1 g O,P Apronal N05CM12 0.25 g O Aprotinin B02AB01 500 TU P Arbutamine C01CA22 Arginine glutamate A05BA01 Arginine hydrochloride B05XB01 Argipressin H01BA06 Arsthinol P01AR01 4/63 Articaine N01BB08 Articaine, combinations N01BB58 Artificial tears and other indifferent preparations S01XA20 Ascorbic acid (vit C) A11GA01 0.2 g O,P Ascorbic acid (vit C) and calcium A11GB01 Asparaginase L01XX02 Astemizole R06AX11 10 mg O Atenolol C07AB03 75 mg O,P Atenolol and other antihypertensives C07FB03 Atenolol and other diuretics C07CB03 Atenolol and other diuretics, combinations C07CB53 Atenolol and thiazides C07BB03 Atenolol, thiazides and other diuretics C07DB01 Atorvastatin C10AA05 10 mg O Atovaquone P01AX06 2.25 g O Atracurium M03AC04 Atropine A03BA01 1.5 mg O,P Atropine S01FA01 Atropine and psycholeptics A03CB03 Attapulgite A07BC04 Attapulgite, combinations A07BC54 Auranofin M01CB03 6 mg O Aurothioglucose M01CB04 2.4 mg P Aurotioprol M01CB05 Azanidazole G01AF13 Azanidazole P01AB04 Azapetine C04AX30 0.15 g O Azapropazone M01AX04 0.75 g O Azatadine R06AX09 2 mg O Azathioprine L04AX01 0.15 g O,P Azelaic acid D10AX03 Azelastine R01AC03 0.56 mg N Azelastine R06AX19 4 mg O Azidamfenicol S01AA25 Azidocillin J01CE04 1.5 g O Azithromycin J01FA10 0.3 g O Azlocillin J01CA09 12 g P Aztreonam J01DF01 4 g P B Bacampicillin J01CA06 1.2 g O Bacitracin D06AX05 Bacitracin R02AB04 Baclofen M03BX01 50 mg O Balsalazide A07EC04 Bambuterol R03CC12 20 mg O Bamethan C04AA31 75 mg O Bamifylline R03DA08 Bamipine D04AA15 Bamipine R06AX01 0.1 g O Barbexaclone N03AA04 Barbital N05CA04 0.5 g O Barbiturates in combination with other drugs N05CB02 Barium sulfate with suspending agents V08BA01 Barium sulfate without suspending agents V08BA02 Barnidipine C08CA12 Batroxobin B02BX03 BCG vaccine L03AX03 Beclamide N03AX30 Beclometasone A07EA07 Beclometasone D07AC15 5/63 Beclometasone R01AD01 0.4 mg N Beclometasone R03BA01 0.8 mg Inhal.aerosol/powder Beclometasone R03BA01 1.5 mg Inhal.solution Beclometasone and antibiotics D07CC04 Befunolol S01ED06 0.2 ml Belladonna total alkaloids A03BA04 1 mg O Belladonna total alkaloids and psycholeptics A03CB02 Bemegride R07AB05 Benazepril C09AA07 7.5 mg O Benazepril and diuretics C09BA07 Bencyclane C04AX11 Bendazac M02AA11 Bendazac S01BC07 Bendroflumethiazide C03AA01 2.5 mg O Bendroflumethiazide and potassium C03AB01 2.5 mg O Bendroflumethiazide and potassium-sparing agents C03EA13 Benfluorex C10AX04 Benorilate N02BA10 3 g O Benoxaprofen M01AE06 Benperidol N05AD07 1.5 mg O Benproperine R05DB02 75 mg O Bentiromide
Load more

Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • Par Drugs and Chemicals Limited
    +91-8048372739 PAR DRUGS AND CHEMICALS LIMITED https://www.indiamart.com/pardrugs/ We are one of the leading Manufacturer of various Inorganic Molecules such as-Magnesium Hydroxide, Aluminium Hydroxide, Magnesium & Aluminum Silicates as well the blends of these molecules such as Magaldrate, Almagate, Hydrotalcite etc. About Us Par Drugs & Chemicals Private Limited incorporated in the year 1982 and proved its competency as the known Manufacturer of various Inorganice Molecules such as- Magnesium Hydroxide, Aluminium Hydroxide, Magnesium Trisilicate, Magnesium & Aluminum Silicates as well the blends of these molecules such as Magaldrate, Almagate, Hydrotalcite etcs. Our products stand high in terms of quality and low whereas price is concerned. Mr. F. V. Savani (Marketing Director) has enabled us to gain prominent position in industry. He ensures that the customer’s needs are efficiently fulfilled in an appropriate manner and they are served as per their demands. We do not compromises in terms of quality of our range and ensure that the customers are served accordingly. Our team ensures that products are manufactured in confirmation with the specific quality standards. Packaging of our range is done carefully so that products may reach the clients end in safe manner. Regular training sessions keep our employees aware of the changes taking place in industry and ensure that they also perform accordingly. Our well-equipped infrastructure has enabled us to carry our business operations in smooth and efficient manner. We have efficiently segregated
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • The Comparison of the Effect Between Alginate-Based Raft-Forming Liquid and Alginate Liquid on Gastroesophageal Reflux Disease and Gastric Ulcer in Rats
    Online - 2455-3891 Vol 10, Issue 12, 2017 Print - 0974-2441 Research Article THE COMPARISON OF THE EFFECT BETWEEN ALGINATE-BASED RAFT-FORMING LIQUID AND ALGINATE LIQUID ON GASTROESOPHAGEAL REFLUX DISEASE AND GASTRIC ULCER IN RATS HAKIM BANGUN1*, ANAYANTI ARIANTO1, RIRIN ASTYA1, GONTAR A SIREGAR2 1Department of Pharmaceutical Technology, Faculty of Pharmacy, Nanomedicine Center, University of Sumatera Utara, Jl. Tri Dharma No. 5, Kampus USU, Medan, Indonesia. 2Department of Internal Medicine, Faculty of Medicine, University of Sumatera Utara, Jl Dr. T. Mansyur No. 5, Kampus USU, Medan, Indonesia. Email: [email protected] Received: 04 July 2017, Revised and Accepted: 16 August 2017 ABSTRACT Objective: The objective of the study was to compare the effect between alginate (Alg)-based raft-forming and Alg liquid on healing gastroesophageal reflux disease (GERD) and gastric ulcer in rats. Methods: Each of the 18 fasted rats was given 1 ml acidified pepsin. Then, rats were divided into three groups. Each group consisted of six rats. Group 1 (negative control) was orally given 1 ml distilled water, Group 2 was given 1 ml Alg-based raft-forming liquid, and Group 3 was given 1 ml Alg liquid. Then, the abdomen of rats was incised under anesthesia with ketamine, and then both their pylorus and the forestomach were ligated to form gastric reflux. After 4 hrs, all rats were killed with chloroform and their esophagus and stomach were examined macroscopically and microscopically (histopathology). Results: On macroscopic observation, all of the Group 1 rats (negative control) showed esophageal lesions and gastric lesions. Four rats of Group 2 (given Alg-based raft-forming) showed no esophageal lesion and two more rats showed a slight lesion, but all of the tested rats showed gastric lesions.
    [Show full text]
  • RAFT FORMING SYSTEM a REVIEW Bhavsar Dhaval Niranjanbhai*, Varde Neha Mahendrakumar, C
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Journal of Drug Delivery and Therapeutics (JDDT) Bhavsar et al Journal of Drug Delivery & Therapeutics; 2012, 2(5), 123-128 123 Available online at http://jddtonline.info REVIEW ARTICLE ADVANCES IN GRDDS: RAFT FORMING SYSTEM A REVIEW Bhavsar Dhaval Niranjanbhai*, Varde Neha Mahendrakumar, C. Sini Surendran, Shah Viral H, Upadhyay UM Dept. of pharmaceutics, Sigma Institute of Pharmacy, Bakrol, Vadodara(Gujarat), India *Corresponding Author’s Ph: +91-9725512814, Email id: [email protected] Received 06 June 2012; Review Completed 26 Aug 2012; Accepted 26 Aug 2012, Available online 15 Sep 2012 ABSTRACT: In recent years several advancements has been made in research and development of Gastro retentive drug delivery system to overcome the drawback of non-site specificity when drug administered orally. In order to understand various physiological difficulties to achieve gastric retention, we have summarized important factors controlling gastric retention time. We have reviewed various gastro retentive approaches designed and developed until now i.e. floating drug dosage systems (FDDS), swelling or expanding systems, mucoadhesive systems, high density system, Raft forming system, magnetic systems. Among these systems, the review summarizes the special focus on raft forming approach which comes under floating drug delivery system. Raft system incorporates alginate gels which have carbonate components react with gastric acid causes bubbles and this enables floating. Finally, Evaluation, advantages, disadvantages, future potential and marketed preparation of raft forming approach in gastro retentive drug delivery systems were covered. Key words-Advances in GRDDS, Raft forming system, alginic acid, gaviscon, INTRODUCTION: Conventional oral delivery is widely used in 4) Drugs with a narrow window of absorption E.g.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Novel and Effective Almagate Enema for Hemorrhagic Chronic Radiation Proctitis and Its Risk Factors
    DOI:http://dx.doi.org/10.7314/APJCP.2016.17.2.631 Novel and Effective Almagate Enema for Hemorrhagic Chronic Radiation Proctitis and its Risk Factors RESEARCH ARTICLE Novel and Effective Almagate Enema for Hemorrhagic Chronic Radiation Proctitis and Risk Factors for Fistula Development Zi-Xu Yuan1,2,3&, Teng-Hui Ma1&, Qing-Hua Zhong1, Huai-Ming Wang1, Xi-Hu Yu 1,3, Qi-Yuan Qin1, Li-Li Chu1, Lei Wang1,3*, Jian-Ping Wang1,3* Abstract Radiation proctitis is a common complication after radiotherapy for pelvic malignant tumors. This study was conducted to assess the efficacy of novel almagate enemas in hemorrhagic chronic radiation proctitis (CRP) and evaluate risk factors related to rectal deep ulcer or fistula secondary to CRP. All patients underwent a colonoscopy to confirm the diagnosis of CRP and symptoms were graded. Typical endoscopic and pathological images, risk factors, and quality of life were also recorded. A total of 59 patients were enrolled. Gynecological cancers composed 93.1% of the primary malignancies. Complete or obvious reduction of bleeding was observed in 90% (53/59) patients after almagate enema. The mean score of bleeding improved from 2.17 to 0.83 (P<0.001) after the enemas. The mean response time was 12 days. No adverse effects were found. Moreover, long-term successful rate in controlling bleeding was 69% and the quality of life was dramatically improved (P=0.001). The efficacy was equivalent to rectal sucralfate, but the almagate with its antacid properties acted more rapidly than sucralfate. Furthermore, we firstly found that moderate to severe anemia was the risk factor of CRP patients who developed rectal deep ulcer or fistulas P( = 0.015).
    [Show full text]